Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.47 USD | -0.68% | -7.55% | 0.00% |
May. 15 | Earnings Flash (SPRO) SPERO THERAPEUTICS Reports Q1 Revenue $9.3M | MT |
Mar. 13 | Transcript : Spero Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024 |
Financials (USD)
Sales 2024 * | 24.13M | Sales 2025 * | 34.33M | Capitalization | 79.36M |
---|---|---|---|---|---|
Net income 2024 * | -71M | Net income 2025 * | -73M | EV / Sales 2024 * | 3.29 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.31 x |
P/E ratio 2024 * |
-1.13
x | P/E ratio 2025 * |
-1.21
x | Employees | 46 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 79.87% |
Latest transcript on Spero Therapeutics, Inc.
1 day | -0.68% | ||
1 week | -7.55% | ||
Current month | +3.52% | ||
1 month | +2.80% | ||
3 months | -2.65% | ||
6 months | +23.53% |
Managers | Title | Age | Since |
---|---|---|---|
Satyavrat Shukla
CEO | Chief Executive Officer | 52 | 21-01-03 |
Ankit Mahadevia
FOU | Founder | 43 | 13-03-31 |
Esther Rajavelu
DFI | Director of Finance/CFO | 46 | Nov. 05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Frank Thomas
BRD | Director/Board Member | 54 | 17-06-30 |
John Pottage
BRD | Director/Board Member | 71 | 18-08-13 |
Scott Jackson
BRD | Director/Board Member | 59 | 20-04-15 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 1.47 | -0.68% | 86,416 |
24-05-23 | 1.48 | -1.66% | 164,323 |
24-05-22 | 1.505 | -0.33% | 187,979 |
24-05-21 | 1.51 | -3.21% | 205,617 |
24-05-20 | 1.56 | -1.89% | 228,942 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 79.36M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- SPRO Stock